Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Roblon - Præsentation af regnskabet for 3. kvartal 2025/26

RBLN B30.09.2026 klo 11.00
HC Andersen Capital

Roblon – Præsentation af regnskabet for 3. kvartal 2025/26

Roblon forventes at offentliggøre sit endelige regnskab for 3. kvartal 2025/26 - tirsdag d. 29. september 2026. Dagen efter - onsdag d. 30. september 2026 kl. 10:00 - har vi fornøjelsen at invitere til en gennemgang af regnskabet. Med fra Roblon til at præsentere og svare på spørgsmål har vi Carsten Michno, der bestrider rollen som både CFO og Co-CEO.

Roblon udsendte i slutningen af august foreløbige tal for 3. kvartal 2025/26, og måtte i den forbindelse nedjustere sine forventninger for anden gang i år. Således venter Roblon nu en omsætning på DKK 150-170 mio. (tidligere DKK 170-210 mio.), et EBITDA før særlige poster på DKK -10 til 0 mio. (tidligere DKK 0-20 mio.) og et EBIT før særlige poster på DKK -20 til -10 mio. (tidligere DKK -10 til 10 mio.). Ledelsen angiver som primær årsag, at en af de største kunder inden for olie- og gas offshore midlertidigt har reduceret indkøbsbehovet som følge af høje lagre, hvilket har påvirket ordreoptag og omsætning mere negativt end tidligere forventet. Hertil kommer, at fremgangen i FOC-produktgruppen er realiseret på et lavere niveau end ventet.

Disclaimer: HC Andersen Capital modtager betaling fra Roblon for en Digital IR abonnementsaftale. /Rasmus Køjborg, CFA kl. 09.30 01/09-2026.

Upcoming webcasts

Recent videos

Catching up with Verve: Q2, the sales build and the full-year outlook
29.09.2026 klo 17.07 Verve Group
Hemnet Group AB, Investor Presentation
29.09.2026 klo 16.00 Hemnet Group
Egetis, FDA Approval
29.09.2026 klo 09.00 Egetis Therapeutics
Could Control Resonant be a massive success for Remedy?
28.09.2026 klo 13.56 Remedy Entertainment
Discount stores | Is retail profitable?
24.09.2026 klo 15.09 Tokmanni Group
View all videos